Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy - Takeaways - MDSpire

Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy

  • By

  • Sophia Kennedy

  • Jerin Thomas

  • Stella D’Arcy

  • Ivie Odia

  • Dev Kamdar

  • Lucio Pereira

  • Danielle Scarola

  • Brett Miles

  • Douglas Frank

  • Charit Taneja

  • Nagashree Seetharamu

  • Rajarsi Mandal

  • May 28, 2026

  • 0 min

Share

  • 1

    Metastatic papillary thyroid carcinoma (PTC) exhibits the highest median GLP-1R mRNA expression among all cancer types analyzed in the TCGA.

  • 2

    Flow cytometric analysis confirmed elevated GLP-1R protein expression in metastatic tissues of both papillary and medullary thyroid carcinomas.

  • 3

    High GLP-1R expression in thyroid cancers is associated with downregulated immune pathway activity and reduced immune cell infiltration.

  • 4

    Distinct immunogenetic transcriptional profiles were identified in thyroid cancers based on GLP-1R expression levels.

  • 5

    The study highlights the need for further investigation into the oncogenic implications of GLP-1R overexpression in thyroid cancer.

Original Source(s)

Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy

  • by Sophia Kennedy, Jerin Thomas, Stella D’Arcy, Ivie Odia, Dev Kamdar, Lucio Pereira, Danielle Scarola, Brett Miles, Douglas Frank, Charit Taneja, Nagashree Seetharamu, Rajarsi Mandal

  • May 28, 2026

Related Content

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report